Project Co-funded
- Project acronym | PHASE
- Project Title | Pharmacovigilance for SMEs in Europe
- Sub-Grant Agreement Number | 2024/100
- Start of the Project | 2024-03-01
- End of the Project | 2024-11-29
Project
The DESIRE Eurocluster project has been launched on September 1st 2022 and will last 36 months. It is composed by 1 business support organisation and 4 clusters from Austria, France, Romania and Poland. It will address the challenges that SMEs face when accessing the European eHealth and Digital Health Market in order to build resilience and facilitate green and digital transition.
PHASE integrates the entire drug life cycle, providing a holistic approach to product safety, spanning from clinical trials to post-marketing. The automation of key processes, especially ADE detection, enhances efficiency, reliability, and patient safety. This optimises workflows, reduces costs, and lowers the carbon footprint. This strategic approach aims to make the tool economically viable and ensures the green transition for budget-constrained SMEs, effectively democratising the adoption of advanced technology in the market. Beyond increasing European self-reliance, the goal is to allow Europe to increase exports to non-European markets.
Goals
At the end of the PHASE project, ITClinical will have developed an AI algorithm to power the Bibliovigilance software with ADE detection and evaluation capabilities. This marks a new era in the Bibliovigilance software, further empowering pharmacovigilance professionals in performing their tasks using ITClinical tools.